We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Lundbeck Research USA, Inc. and BioFocus Sign Compound Management Agreement

News   Jan 26, 2011

 
Lundbeck Research USA, Inc. and BioFocus Sign Compound Management Agreement
 
 
Advertisement
 

RELATED ARTICLES

Existing Alcoholism Drug Potentially Effective Against COVID-19

News

Chemists have used molecular modeling to identify two existing drugs that could be used to fight SARS-CoV-2. These are disulfiram, which is used to treat alcoholism, and neratinib, an experimental drug being used to treat breast cancer.

READ MORE

Potential New Treatment Tactic for Acute Myeloid Leukemia

News

Researchers demonstrate that factors produced by bone marrow support cells allow leukemia cells to survive treatment with quizartinib. When quizartinib was combined with another tyrosine kinase inhibitor called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death.

READ MORE

Diabetes Drug Candidate Shows Promise in Cell and Mouse Models

News

A new drug candidate SRI-37330 was tested on isolated human and mouse pancreatic islets, mouse and rat cell cultures and animal models of both Type 1 and Type 2 diabetes, and was shown to significantly improve four detrimental characteristics of diabetes.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE